21st Apr 2017 13:36
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Ms E Walmsley | ||||||||
b) | Position/status | Chief Executive Officer | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
5,665.610 £16.47
| ||||||||
e) | Date of the transaction | 2017-04-18 | ||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr R G Connor | ||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
3,119.129 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr L Debruyne | ||||||
b) | Position/status | President, Global Vaccines | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
790.455 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr S Dingemans | ||||||
b) | Position/status | Chief Financial Officer | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
6,193.410 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr N Hirons | ||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
1,385.140 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr S A Hussain | ||||||
b) | Position/status | President, Global Pharmaceuticals | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
6,609.140 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr D S Redfern | ||||||
b) | Position/status | Chief Strategy Officer | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
2,356.953 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Ms C Thomas | ||||||
b) | Position/status | SVP, HR | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
3,047.766 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||||||
a) | Name | Mr P C Thomson | |||||||
b) | Position/status | President, Global Affairs | |||||||
c) | Initial notification/ amendment | Initial notification | |||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
a) | Name | GlaxoSmithKline plc | |||||||
b) | LEI | 5493000HZTVUYLO1D793 | |||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | |||||||
c) | Price(s) and volume(s) |
| |||||||
d) | Aggregated information
Aggregated volume Price |
1,758.202 £16.47
| |||||||
e) | Date of the transaction | 2017-04-18 | |||||||
f) | Place of the transaction
| n/a | |||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Dr P J T Vallance | ||||||
b) | Position/status | President, R&D | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
6,736.858 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mrs V A Whyte | ||||||
b) | Position/status | Company Secretary | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
361.199 £16.47
| ||||||
e) | Date of the transaction | 2017-04-18 | ||||||
f) | Place of the transaction
| n/a |
Related Shares:
Glaxosmithkline